BIOMAT Database Logo BIOMAT Database Logo

Clearance of 131I-labeled murine monoclonal antibody from patients' blood by intravenous human anti-murine immunoglobulin antibody. 1990

J S Stewart, and G B Sivolapenko, and V Hird, and K A Davies, and M Walport, and M A Ritter, and A A Epenetos
Imperial Cancer Research Fund, Hammersmith Hospital, London, United Kingdom.

Five patients treated with intraperitoneal 131I-labeled mouse monoclonal antibody for ovarian cancer also received i.v. exogenous polyclonal human anti-murine immunoglobulin antibody. The pharmacokinetics of 131I-labeled monoclonal antibody in these patients were compared with those of 28 other patients receiving i.p.-radiolabeled monoclonal antibody for the first time without exogenous human anti-murine immunoglobulin, and who had no preexisting endogenous human anti-murine immunoglobulin antibody. Patients receiving i.v. human anti-murine immunoglobulin antibody demonstrated a rapid clearance of 131I-labeled monoclonal antibody from their circulation. The (mean) maximum 131I blood content was 11.4% of the injected activity in patients receiving human anti-murine immunoglobulin antibody compared to 23.3% in patients not given human anti-murine immunoglobulin antibody. Intravenous human anti-murine immunoglobulin antibody decreased the radiation dose to bone marrow (from 131I-labeled monoclonal antibody in the vascular compartment) 4-fold. Following the injection of human anti-murine immunoglobulin antibody, 131I-monoclonal/human anti-murine immunoglobulin antibody immune complexes were rapidly transported to the liver. Antibody dehalogenation in the liver was rapid, with 87% of the injected 131I excreted in 5 days. Despite the efficient hepatic uptake of immune complexes, dehalogenation of monoclonal antibody was so rapid that the radiation dose to liver parenchyma from circulating 131I was decreased 4-fold rather than increased. All patients developed endogenous human anti-murine immunoglobulin antibody 2 to 3 weeks after treatment.

UI MeSH Term Description Entries
D007116 Immunization, Passive Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER). Convalescent Plasma Therapy,Immunoglobulin Therapy,Immunotherapy, Passive,Normal Serum Globulin Therapy,Passive Antibody Transfer,Passive Transfer of Immunity,Serotherapy,Passive Immunotherapy,Therapy, Immunoglobulin,Antibody Transfer, Passive,Passive Immunization,Therapy, Convalescent Plasma,Transfer, Passive Antibody
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D007457 Iodine Radioisotopes Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes. Radioisotopes, Iodine
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008562 Membrane Glycoproteins Glycoproteins found on the membrane or surface of cells. Cell Surface Glycoproteins,Surface Glycoproteins,Cell Surface Glycoprotein,Membrane Glycoprotein,Surface Glycoprotein,Glycoprotein, Cell Surface,Glycoprotein, Membrane,Glycoprotein, Surface,Glycoproteins, Cell Surface,Glycoproteins, Membrane,Glycoproteins, Surface,Surface Glycoprotein, Cell,Surface Glycoproteins, Cell
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D011879 Radiotherapy Dosage The total amount of radiation absorbed by tissues as a result of radiotherapy. Dosage, Radiotherapy,Dosages, Radiotherapy,Radiotherapy Dosages
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J S Stewart, and G B Sivolapenko, and V Hird, and K A Davies, and M Walport, and M A Ritter, and A A Epenetos
Experimental radiotherapy of murine lymphoma with 131I-labeled anti-Thy 1.1 monoclonal antibody.
April 1985, Cancer research,
J S Stewart, and G B Sivolapenko, and V Hird, and K A Davies, and M Walport, and M A Ritter, and A A Epenetos
Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy.
February 1985, Cancer research,
J S Stewart, and G B Sivolapenko, and V Hird, and K A Davies, and M Walport, and M A Ritter, and A A Epenetos
Radioimmunotherapy of human colon cancer xenografts with 131I-labeled anti-CEA monoclonal antibody.
February 2010, Bioconjugate chemistry,
J S Stewart, and G B Sivolapenko, and V Hird, and K A Davies, and M Walport, and M A Ritter, and A A Epenetos
Pre-existing anti-mouse immunoglobulin in a patient receiving 131I-murine monoclonal antibody for radioimmunolocalisation.
February 1986, British journal of cancer,
J S Stewart, and G B Sivolapenko, and V Hird, and K A Davies, and M Walport, and M A Ritter, and A A Epenetos
Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6.
May 1988, Cancer research,
J S Stewart, and G B Sivolapenko, and V Hird, and K A Davies, and M Walport, and M A Ritter, and A A Epenetos
Human anti-murine immunoglobulin responses and immune functions in cancer patients receiving murine monoclonal antibody therapy.
January 1991, Human antibodies and hybridomas,
J S Stewart, and G B Sivolapenko, and V Hird, and K A Davies, and M Walport, and M A Ritter, and A A Epenetos
Clearance kinetics and external dosimetry of 131I-labeled murine and humanized monoclonal antibody A33 in patients with colon cancer: radiation safety implications.
May 2009, Health physics,
J S Stewart, and G B Sivolapenko, and V Hird, and K A Davies, and M Walport, and M A Ritter, and A A Epenetos
Radioimmunotherapy of the GW-39 human colonic tumor xenograft with 131I-labeled murine monoclonal antibody to carcinoembryonic antigen.
November 1987, Cancer research,
J S Stewart, and G B Sivolapenko, and V Hird, and K A Davies, and M Walport, and M A Ritter, and A A Epenetos
Anti-proliferative effects induced by anti-CD4 human/murine chimeric antibody and murine anti-CD4 monoclonal antibody.
January 1999, Journal of Tongji Medical University = Tong ji yi ke da xue xue bao,
J S Stewart, and G B Sivolapenko, and V Hird, and K A Davies, and M Walport, and M A Ritter, and A A Epenetos
Biodistribution of 131I-labeled anti-CK8 monoclonal antibody in HNSCC in xenotransplanted SCID mice.
October 2011, Anticancer research,
Copied contents to your clipboard!